Skip to main content
. 2020 Sep 22;12(9):2713. doi: 10.3390/cancers12092713

Figure 1.

Figure 1

Flowchart of the study design with indication of numbers of patients from the original cohort included in every analysis. IDC—invasive ductal carcinoma, ER—estrogen receptor protein status, PR—progesterone receptor protein status, IHC—immunohistochemistry, FGFR2—fibroblast growth factor receptor 2 protein, PR(mol)—molecular signature progesterone receptor-dependent genes, OS—overall survival, DFS—disease-free survival.